Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FBXW7 |
Variant | C453fs |
Impact List | frameshift |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | FBXW7 C453fs results in a change in the amino acid sequence of the Fbxw7 protein beginning at aa 453 of 707, likely resulting in premature truncation of the functional protein (UniProt.org). C453fs has not been characterized however, due to the effects of other truncation mutations downstream of C453 (PMID: 24838835), is predicted to lead to a loss of Fbxw7 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
FBXW7 mutant FBXW7 inact mut FBXW7 C453fs |
Transcript | NM_033632.3 |
gDNA | chr4:g.(152328269_152328270) |
cDNA | c.(1357_1356) |
Protein | p.C453fs |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_047415899.1 | chr4:g.(152328269_152328270) | c.(1357_1356) | p.C453fs | RefSeq | GRCh38/hg38 |
XM_047415901.1 | chr4:g.(152328269_152328270) | c.(1357_1356) | p.C453fs | RefSeq | GRCh38/hg38 |
NM_001349798.1 | chr4:g.(152328269_152328270) | c.(1357_1356) | p.C453fs | RefSeq | GRCh38/hg38 |
XM_011532085 | chr4:g.(152328269_152328270) | c.(1357_1356) | p.C453fs | RefSeq | GRCh38/hg38 |
XM_017008362 | chr4:g.(152328269_152328270) | c.(1357_1356) | p.C453fs | RefSeq | GRCh38/hg38 |
XM_011532084 | chr4:g.(152328269_152328270) | c.(1357_1356) | p.C453fs | RefSeq | GRCh38/hg38 |
NM_033632.3 | chr4:g.(152328269_152328270) | c.(1357_1356) | p.C453fs | RefSeq | GRCh38/hg38 |
XM_011532085.2 | chr4:g.(152328269_152328270) | c.(1357_1356) | p.C453fs | RefSeq | GRCh38/hg38 |
XM_024454122.1 | chr4:g.(152328269_152328270) | c.(1357_1356) | p.C453fs | RefSeq | GRCh38/hg38 |
XM_024454121.1 | chr4:g.(152328269_152328270) | c.(1357_1356) | p.C453fs | RefSeq | GRCh38/hg38 |
XM_024454123.2 | chr4:g.(152328269_152328270) | c.(1357_1356) | p.C453fs | RefSeq | GRCh38/hg38 |
NM_033632 | chr4:g.(152328269_152328270) | c.(1357_1356) | p.C453fs | RefSeq | GRCh38/hg38 |
XM_047415900.1 | chr4:g.(152328269_152328270) | c.(1357_1356) | p.C453fs | RefSeq | GRCh38/hg38 |
NM_001349798.2 | chr4:g.(152328269_152328270) | c.(1357_1356) | p.C453fs | RefSeq | GRCh38/hg38 |
XM_011532083 | chr4:g.(152328269_152328270) | c.(1357_1356) | p.C453fs | RefSeq | GRCh38/hg38 |
XM_047415897.1 | chr4:g.(152328269_152328270) | c.(1357_1356) | p.C453fs | RefSeq | GRCh38/hg38 |
XM_047415898.1 | chr4:g.(152328269_152328270) | c.(1357_1356) | p.C453fs | RefSeq | GRCh38/hg38 |
NM_018315.4 | chr4:g.(152326053_152326054) | c.(1357_1356) | p.C453fs | RefSeq | GRCh38/hg38 |
NM_018315.5 | chr4:g.(152326053_152326054) | c.(1357_1356) | p.C453fs | RefSeq | GRCh38/hg38 |
XM_011532084.3 | chr4:g.(152328269_152328270) | c.(1357_1356) | p.C453fs | RefSeq | GRCh38/hg38 |
NM_033632.3 | chr4:g.(152328269_152328270) | c.(1357_1356) | p.C453fs | RefSeq | GRCh38/hg38 |
NM_018315 | chr4:g.(152326053_152326054) | c.(1357_1356) | p.C453fs | RefSeq | GRCh38/hg38 |
XM_011532085.3 | chr4:g.(152328269_152328270) | c.(1357_1356) | p.C453fs | RefSeq | GRCh38/hg38 |
XM_024454123.1 | chr4:g.(152328269_152328270) | c.(1357_1356) | p.C453fs | RefSeq | GRCh38/hg38 |
XM_024454124.1 | chr4:g.(152328269_152328270) | c.(1357_1356) | p.C453fs | RefSeq | GRCh38/hg38 |
XM_011532084.2 | chr4:g.(152328269_152328270) | c.(1357_1356) | p.C453fs | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|